A shareholder has accused pharmaceutical company MEI Pharma Inc. of inflating stock prices by overhyping the trial success of a blood cancer treatment.

The derivative suit filed Wednesday in the U.S. District Court for the District of Delaware by shareholder Peter D’Arcy alleges 10 of the San Diego-based company’s officers and directors intentionally gave investors nonspecific information and failed to disclose the risk factors of Pracinostat, a drug for which an international clinical trial was halted in July just before MEI’s share price dropped more than 18% in a day.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Advance® Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]